26
|
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 2019; 30:1487-1495. [PMID: 31240302 PMCID: PMC6771222 DOI: 10.1093/annonc/mdz199] [Citation(s) in RCA: 126] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. PATIENTS AND METHODS Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients were enrolled in two sequential cohorts (cohort 1300 mg/m2; cohort 2600 mg/m2); additional patients were enrolled into a dose-expansion cohort (cohort 3600 mg/m2). The primary end point was the objective response rate [ORR: complete and partial response (PR)]; secondary end points included clinical benefit [ORR+stable disease (SD)], progression-free survival, safety/tolerability, and zolbetuximab pharmacokinetic profile. RESULTS From September 2010 to September 2012, 54 patients were enrolled (cohort 1, n = 4; cohort 2, n = 6; cohort 3, n = 44). Three patients in cohort 1 and 25 patients in cohorts 2/3 received at least 5 infusions. Antitumour activity data were available for 43 patients, of whom 4 achieved PR (ORR 9%) and 6 (14%) had SD for a clinical benefit rate of 23%. In a subgroup of patients with moderate-to-high CLDN18.2 expression in ≥70% of tumour cells, ORR was 14% (n = 4/29). Treatment-related adverse events occurred in 81.5% (n = 44/54) patients; nausea (61%), vomiting (50%), and fatigue (22%) were the most frequent. CONCLUSIONS Zolbetuximab monotherapy was well tolerated and exhibited antitumour activity in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinomas, with response rates similar to those reported for single-agent targeted agents in gastric/GEJ cancer trials. CLINICALTRIALS.GOV NUMBER NCT01197885.
Collapse
|
27
|
Bhandari B, Bian J, Bilton K, Callahan C, Chaves J, Chen H, Cline D, Cooper RL, Danielson D, Danielson J, Dokania N, Elliott S, Fernandes S, Gardiner S, Garvey G, Gehman V, Giuliani F, Glavin S, Gold M, Grant C, Guardincerri E, Haines T, Higuera A, Ji JY, Kadel R, Kamp N, Karlin A, Ketchum W, Koerner LW, Lee D, Lee K, Liu Q, Locke S, Louis WC, Manalaysay A, Maricic J, Martin E, Martinez MJ, Martynenko S, Mauger C, McGrew C, Medina J, Medina PJ, Mills A, Mills G, Mirabal-Martinez J, Olivier A, Pantic E, Philipbar B, Pitcher C, Radeka V, Ramsey J, Rielage K, Rosen M, Sanchez AR, Shin J, Sinnis G, Smy M, Sondheim W, Stancu I, Sterbenz C, Sun Y, Svoboda R, Taylor C, Teymourian A, Thorn C, Tull CE, Tzanov M, Van de Water RG, Walker D, Walsh N, Wang H, Wang Y, Yanagisawa C, Yarritu A, Yoo J. First Measurement of the Total Neutron Cross Section on Argon between 100 and 800 MeV. PHYSICAL REVIEW LETTERS 2019; 123:042502. [PMID: 31491269 DOI: 10.1103/physrevlett.123.042502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 05/23/2019] [Indexed: 06/10/2023]
Abstract
We report the first measurement of the neutron cross section on argon in the energy range of 100-800 MeV. The measurement was obtained with a 4.3-h exposure of the Mini-CAPTAIN detector to the WNR/LANSCE beam at LANL. The total cross section is measured from the attenuation coefficient of the neutron flux as it traverses the liquid argon volume. A set of 2631 candidate interactions is divided in bins of the neutron kinetic energy calculated from time-of-flight measurements. These interactions are reconstructed with custom-made algorithms specifically designed for the data in a time projection chamber the size of the Mini-CAPTAIN detector. The energy averaged cross section is 0.91±0.10(stat)±0.09(syst) b. A comparison of the measured cross section is made to the GEANT4 and FLUKA event generator packages, where the energy averaged cross sections in this range are 0.60 and 0.68 b, respectively.
Collapse
|
28
|
Somroo AA, Ur Rehman K, Zheng L, Cai M, Xiao X, Hu S, Mathys A, Gold M, Yu Z, Zhang J. Influence of Lactobacillus buchneri on soybean curd residue co-conversion by black soldier fly larvae (Hermetia illucens) for food and feedstock production. WASTE MANAGEMENT (NEW YORK, N.Y.) 2019; 86:114-122. [PMID: 30902235 DOI: 10.1016/j.wasman.2019.01.022] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 12/07/2018] [Accepted: 01/13/2019] [Indexed: 06/09/2023]
Abstract
Black soldier fly larvae (BSFL), Hermetia illucens (Diptera: Stratiomyidae) can reduce environmental pollution and convert organic wastes into biomass that is rich in protein and fat. The influence of the nutritional characteristics of organic waste on BSFL characteristics relevant for food and feed safety remains poorly understood. To evaluate the conversion of soybean curd residues (SCR) into high-quality animal-derived proteins and fats for human and livestock consumption, this study assessed the co-conversion efficacy, nutrient composition, safety, and anti-nutritional factor concentrations in BSFL after the development on SCR with Lactobacillus buchneri (L3-9). SCR was pretreated with L. buchneri (108 cfu/ml), and then BSFL was employed for conversion. BSFL fed with SCR and L. buchneri had a significantly higher dry mass reduction (55.7 ± 0.9%), bioconversion rate (6.9 ± 0.3%), crude protein content (55.3 ± 0.6%), and fat content (30.0 ± 0.6%) than SCR (49.0 ± 0.7%, 5.0 ± 0.3%, 52.8 ± 0.3%, and 26.1 ± 0.8%, respectively) and artificial feed (43.9 ± 0.8%, 3.9 ± 0.1%, 50.3 ± 0.4%, and 24.3 ± 0.4%, respectively). However, the feed conversion ratio (8.0 ± 0.3), of BSFL fed with SCR and L. buchneri was lower than that of the BSFL fed with SCR (9.8 ± 0.1) and artificial feed (11.1 ± 0.5). In addition, BSFL had satisfactory concentrations of all essential amino acids and fatty acids required for human consumption as recommended by WHO/FAO/UNU. The heavy metals and anti-nutritional factor concentrations were within the safety intake levels for food and feedstock. Therefore, the addition of L. buchneri with BSFL on SCR did not only increase co-conversion performance but also enhanced the nutritional value of BSFL.
Collapse
|
29
|
Gold M, Tomberlin JK, Diener S, Zurbrügg C, Mathys A. Decomposition of biowaste macronutrients, microbes, and chemicals in black soldier fly larval treatment: A review. WASTE MANAGEMENT (NEW YORK, N.Y.) 2018; 82:302-318. [PMID: 30509593 DOI: 10.1016/j.wasman.2018.10.022] [Citation(s) in RCA: 138] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 09/17/2018] [Accepted: 10/12/2018] [Indexed: 06/09/2023]
Abstract
Processing of biowaste with larvae of the black soldier fly, Hermetia illucens L. (Diptera: Stratiomyidae), is an emerging waste treatment technology. Larvae grown on biowaste can be a relevant raw material for animal feed production and can therefore provide revenues for financially viable waste management systems. In addition, when produced on biowaste, insect-based feeds can be more sustainable than conventional feeds. Among others, the scalability of the technology will depend on the availability of large amounts of biowaste with a high process performance (e.g. bioconversion of organic matter to proteins and lipids) and microbial and chemical product safety. Currently, in contrast to other waste treatment technologies, such as composting or anaerobic digestion, the process performance is variable and the processes driving the decomposition of biowaste macronutrients, inactivation of microbes and fate of chemicals is poorly understood. This review presents the first summary of the most important processes involved in black soldier fly larvae (BSFL) treatment, based on the available knowledge concerning five well-studied fly species. This is a starting point to increase understanding regarding the processes of this technology, with the potential to increase its efficiency and uptake, and support the development of appropriate regulations. Based on this review, formulating different types of biowaste, e.g. to produce a diet with a similar protein content, a balanced amino acid profile and/or pre- and co-treatment of biowaste with beneficial microbes, has the potential to increase process performance. Following harvest, larvae require heat or other treatments for microbial inactivation and safety.
Collapse
|
30
|
Gold M, Harada H, Therrien JD, Nishida T, Cunningham M, Semiyaga S, Fujii S, Dorea C, Nguyen VA, Strande L. Cross-country analysis of faecal sludge dewatering. ENVIRONMENTAL TECHNOLOGY 2018; 39:3077-3087. [PMID: 28866955 DOI: 10.1080/09593330.2017.1374472] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 08/21/2017] [Indexed: 06/07/2023]
Abstract
Dewatering of faecal sludge (FS) is indispensable for adequate FS management. However, comprehensive knowledge is lacking on FS dewatering performance. This study compared the dewatering performance of FS from different countries and onsite sanitation technologies, to assess influential characteristics on dewatering, and to compare dewatering performance of FS with wastewater sludge. We collected 73 FS samples from septic tanks, lined pit latrines, unlined pit latrines and johkasou tanks in Uganda, Vietnam and Japan, and 18 samples of wastewater sludge in Switzerland. Capillary suction time (CST) and total solids (TS) of centrifuged sludge (%TSfinal) were determined as metrics of dewatering rate and dewaterability, respectively, together with relevant sludge characteristics. Data were analysed by bootstrapping comparison of median results of each sample category and by bootstrapping multiple regression analysis to quantify the relative importance of sludge characteristics on dewatering performance. Results showed that the dewatering rate was significantly different between FS from different technologies, whereas dewaterability was significantly different within the same technology. FS had a significantly lower dewatering rate than wastewater sludge. In contrast, FS dewaterability was greater than wastewater sludge. However, this could be attributed to higher concentrations of sand in FS. Electrochemical properties such as NH4-N and surface charge had the strongest correlation to dewatering rate, and solid properties such as sand content and total volatile solids to dewaterability. The results identify potential characteristics that could explain and predict the high variability of FS dewatering performance that is observed in the field.
Collapse
|
31
|
Dalby J, Dettmann M, Gold M. Implementing an enhanced long-acting reversible contraception (LARC) curriculum and training for residents into a family medicine residency program. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Jabulowsky R, Loquai C, Derhovanessian E, Mitzel-Rink H, Utikal J, Hassel J, Kaufmann R, Pinter A, Diken M, Gold M, Heesen L, Schreeb K, Schwarck-Kokarakis D, Kreiter S, Gaiser M, Jäger D, Grabbe S, Türeci Ö, Sahin U. A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Best KP, Sullivan TR, Palmer DJ, Gold M, Martin J, Kennedy D, Makrides M. Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood - a longitudinal analysis of long-term follow-up of a randomized controlled trial. World Allergy Organ J 2018; 11:10. [PMID: 29977437 PMCID: PMC6003086 DOI: 10.1186/s40413-018-0190-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 05/18/2018] [Indexed: 11/10/2022] Open
Abstract
Background Randomized controlled trials of prenatal omega (ω-3) long chain polyunsaturated fatty acid (LCPUFA) supplementation are suggestive of some protective effects on allergic sensitization and symptoms of allergic disease in childhood. Due to the nature of the atopic march, investigation of any effects of this prenatal intervention may be most informative when consistently assessed longitudinally during childhood. Methods Follow-up of children (n = 706) with familial risk of allergy from the Docosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. The intervention group received fish oil capsules (900 mg of ω-3 LCPUFA) daily from <21 weeks' gestation until birth; the control group received vegetable oil capsules without ω-3 LCPUFA. This new longitudinal analysis reports previously unpublished data collected at 1 and 3 years of age. The allergic disease symptom data at 1, 3 and 6 years of age were consistently reported by parents using the "International Study of Asthma and Allergies in Childhood" (ISAAC) questionnaire. Sensitization was determined by skin prick test to age specific, common allergen extracts. Results Changes over time in symptoms of allergic disease with sensitization (IgE-mediated) and sensitization did not differ between the groups; interaction p = 0.49, p = 0.10, respectively. Averaged across the 1, 3 and 6-year assessments, there were no significant effects of prenatal ω-3 LCPUFA supplementation on IgE-mediated allergic disease symptoms (adjusted relative risk 0.88 (95% CI 0.69, 1.12), p = 0.29) or sensitization (adjusted relative risk 0.97 (95% CI 0.82, 1.15), p = 0.76). Sensitization patterns to common allergens were consistent with the atopic march, with egg sensitization at 1 year strongly associated with house dust mite sensitization at 6 years, (p < 0.0001). Discussion Although there is some evidence to suggest that maternal supplementation with 900mg ω-3 LCPUFA has a protective effect on early symptoms of allergic disease and sensitization in the offspring, we did not observe any differences in the progression of disease over time in this longitudinal analysis. Further investigation into the dose and timing of ω-3 LCPUFA supplementation, including long-term follow up of children using consistent outcome reporting, is essential to determine whether this intervention may be of benefit as a primary prevention strategy for allergic disease. Conclusion Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization throughout childhood from 1 to 6 years. Trial registration Australian New Zealand Clinical Trials Registry (ACTRN); DOMInO trial ACTRN12605000569606, early childhood allergy follow up ACTRN12610000735055 and 6-year allergy follow up ACTRN12615000498594.
Collapse
|
34
|
Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, Dobos K, Gold M, Hopewell PC, Lewinsohn DM. Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis. PLoS One 2018; 13:e0195392. [PMID: 29787561 PMCID: PMC5963792 DOI: 10.1371/journal.pone.0195392] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 03/21/2018] [Indexed: 11/19/2022] Open
Abstract
Background The roles of host and pathogen factors in determining innate immune responses to M. tuberculosis are not fully understood. In this study, we examined host macrophage immune responses of 3 race/ethnic groups to 3 genetically and geographically diverse M. tuberculosis lineages. Methods Monocyte-derived macrophages from healthy Filipinos, Chinese and non-Hispanic White study participants (approximately 45 individuals/group) were challenged with M. tuberculosis whole cell lysates of clinical strains Beijing HN878 (lineage 2), Manila T31 (lineage 1), CDC1551 (lineage 4), the reference strain H37Rv (lineage 4), as well as with Toll-like receptor 2 agonist lipoteichoic acid (TLR2/LTA) and TLR4 agonist lipopolysaccharide (TLR4/LPS). Following overnight incubation, multiplex assays for nine cytokines: IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IFNγ, TNFα, and GM-CSF, were batch applied to supernatants. Results Filipino macrophages produced less IL-1, IL-6, and more IL-8, compared to macrophages from Chinese and Whites. Race/ethnicity had only subtle effects or no impact on the levels of IL-10, IL-12p70, TNFα and GM-CSF. In response to the Toll-like receptor 2 agonist lipoteichoic acid (TLR2/LTA), Filipino macrophages again had lower IL-1 and IL-6 responses and a higher IL-8 response, compared to Chinese and Whites. The TLR2/LTA-stimulated Filipino macrophages also produced lower amounts of IL-10, TNFα and GM-CSF. Race/ethnicity had no impact on IL-12p70 levels released in response to TLR2/LTA. The responses to TLR4 agonist lipopolysaccharide (TLR4/LPS) were similar to the TLR2/LTA responses, for IL-1, IL-6, IL-8, and IL-10. However, TLR4/LPS triggered the release of less IL-12p70 from Filipino macrophages, and less TNFα from White macrophages. Conclusions Both host race/ethnicity and pathogen strain influence the innate immune response. Such variation may have implications for the development of new tools across TB therapeutics, immunodiagnostics and vaccines.
Collapse
|
35
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland KR, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Canelli F, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d'Ascenzo N, Datta M, de Barbaro P, Demortier L, Deninno M, D'Errico M, Devoto F, Di Canto A, Di Ruzza B, Dittmann JR, Donati S, D'Onofrio M, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Farrington S, Fernández Ramos JP, Field R, Flanagan G, Forrest R, Franklin M, Freeman JC, Frisch H, Funakoshi Y, Galloni C, Garfinkel AF, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grosso-Pilcher C, Guimaraes da Costa J, Hahn SR, Han JY, Happacher F, Hara K, Hare M, Harr RF, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes RE, Husemann U, Hussein M, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jindariani S, Jones M, Joo KK, Jun SY, Junk TR, Kambeitz M, Kamon T, Karchin PE, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen AT, Lammel S, Lancaster M, Lannon K, Latino G, Lee HS, Lee JS, Leo S, Leone S, Lewis JD, Limosani A, Lipeles E, Lister A, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Marchese L, Margaroli F, Marino P, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Mesropian C, Miao T, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello MJ, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Nigmanov T, Nodulman L, Noh SY, Norniella O, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Pranko A, Prokoshin F, Ptohos F, Punzi G, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner JL, Ruffini F, Ruiz A, Russ J, Rusu V, Sakumoto WK, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt EE, Schwarz T, Scodellaro L, Scuri F, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sliwa K, Smith JR, Snider FD, Song H, Sorin V, St Denis R, Stancari M, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis C, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang SM, Waters D, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Wilson JS, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfmeister H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Zanetti AM, Zeng Y, Zhou C, Zucchelli S. Search for the Exotic Meson X(5568) with the Collider Detector at Fermilab. PHYSICAL REVIEW LETTERS 2018; 120:202006. [PMID: 29864341 DOI: 10.1103/physrevlett.120.202006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 03/05/2018] [Indexed: 06/08/2023]
Abstract
A search for the exotic meson X(5568) decaying into the B_{s}^{0}π^{±} final state is performed using data corresponding to 9.6 fb^{-1} from pp[over ¯] collisions at sqrt[s]=1960 GeV recorded by the Collider Detector at Fermilab. No evidence for this state is found and an upper limit of 6.7% at the 95% confidence level is set on the fraction of B_{s}^{0} produced through the X(5568)→B_{s}^{0}π^{±} process.
Collapse
|
36
|
Aaltonen T, Abazov VM, Abbott B, Acharya BS, Adams M, Adams T, Agnew JP, Alexeev GD, Alkhazov G, Alton A, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Askew A, Atkins S, Auerbach B, Augsten K, Aurisano A, Aushev V, Aushev Y, Avila C, Azfar F, Badaud F, Badgett W, Bae T, Bagby L, Baldin B, Bandurin DV, Banerjee S, Barbaro-Galtieri A, Barberis E, Baringer P, Barnes VE, Barnett BA, Barria P, Bartlett JF, Bartos P, Bassler U, Bauce M, Bazterra V, Bean A, Bedeschi F, Begalli M, Behari S, Bellantoni L, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Beuselinck R, Bhat PC, Bhatia S, Bhatnagar V, Bhatti A, Bland KR, Blazey G, Blessing S, Bloom K, Blumenfeld B, Bocci A, Bodek A, Boehnlein A, Boline D, Boos EE, Borissov G, Bortoletto D, Borysova M, Boudreau J, Boveia A, Brandt A, Brandt O, Brigliadori L, Brochmann M, Brock R, Bromberg C, Bross A, Brown D, Brucken E, Bu XB, Budagov J, Budd HS, Buehler M, Buescher V, Bunichev V, Burdin S, Burkett K, Busetto G, Bussey P, Buszello CP, Butti P, Buzatu A, Calamba A, Camacho-Pérez E, Camarda S, Campanelli M, Canelli F, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Casey BCK, Castilla-Valdez H, Castro A, Catastini P, Caughron S, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chakrabarti S, Chan KM, Chandra A, Chapelain A, Chapon E, Chen G, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Cho SW, Choi S, Chokheli D, Choudhary B, Cihangir S, Claes D, Clark A, Clarke C, Clutter J, Convery ME, Conway J, Cooke M, Cooper WE, Corbo M, Corcoran M, Cordelli M, Couderc F, Cousinou MC, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, Cuth J, Cutts D, Das A, d'Ascenzo N, Datta M, Davies G, de Barbaro P, de Jong SJ, De La Cruz-Burelo E, Déliot F, Demina R, Demortier L, Deninno M, Denisov D, Denisov SP, D'Errico M, Desai S, Deterre C, DeVaughan K, Devoto F, Di Canto A, Di Ruzza B, Diehl HT, Diesburg M, Ding PF, Dittmann JR, Dominguez A, Donati S, D'Onofrio M, Dorigo M, Driutti A, Drutskoy A, Dubey A, Dudko LV, Duperrin A, Dutt S, Eads M, Ebina K, Edgar R, Edmunds D, Elagin A, Ellison J, Elvira VD, Enari Y, Erbacher R, Errede S, Esham B, Evans H, Evdokimov A, Evdokimov VN, Farrington S, Fauré A, Feng L, Ferbel T, Fernández Ramos JP, Fiedler F, Field R, Filthaut F, Fisher W, Fisk HE, Flanagan G, Forrest R, Fortner M, Fox H, Franc J, Franklin M, Freeman JC, Frisch H, Fuess S, Funakoshi Y, Galloni C, Garbincius PH, Garcia-Bellido A, García-González JA, Garfinkel AF, Garosi P, Gavrilov V, Geng W, Gerber CE, Gerberich H, Gerchtein E, Gershtein Y, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Ginther G, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gogota O, Gold M, Goldin D, Golossanov A, Golovanov G, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grannis PD, Greder S, Greenlee H, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grosso-Pilcher C, Grünendahl S, Grünewald MW, Guillemin T, Guimaraes da Costa J, Gutierrez G, Gutierrez P, Hahn SR, Haley J, Han JY, Han L, Happacher F, Hara K, Harder K, Hare M, Harel A, Harr RF, Harrington-Taber T, Hatakeyama K, Hauptman JM, Hays C, Hays J, Head T, Hebbeker T, Hedin D, Hegab H, Heinrich J, Heinson AP, Heintz U, Hensel C, Heredia-De La Cruz I, Herndon M, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hoang T, Hobbs JD, Hocker A, Hoeneisen B, Hogan J, Hohlfeld M, Holzbauer JL, Hong Z, Hopkins W, Hou S, Howley I, Hubacek Z, Hughes RE, Husemann U, Hussein M, Huston J, Hynek V, Iashvili I, Ilchenko Y, Illingworth R, Introzzi G, Iori M, Ito AS, Ivanov A, Jabeen S, Jaffré M, James E, Jang D, Jayasinghe A, Jayatilaka B, Jeon EJ, Jeong MS, Jesik R, Jiang P, Jindariani S, Johns K, Johnson E, Johnson M, Jonckheere A, Jones M, Jonsson P, Joo KK, Joshi J, Jun SY, Jung AW, Junk TR, Juste A, Kajfasz E, Kambeitz M, Kamon T, Karchin PE, Karmanov D, Kasmi A, Kato Y, Katsanos I, Kaur M, Kehoe R, Kermiche S, Ketchum W, Keung J, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YN, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kiselevich I, Kohli JM, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kozelov AV, Kraus J, Kreps M, Kroll J, Kruse M, Kuhr T, Kumar A, Kupco A, Kurata M, Kurča T, Kuzmin VA, Laasanen AT, Lammel S, Lammers S, Lancaster M, Lannon K, Latino G, Lebrun P, Lee HS, Lee HS, Lee JS, Lee SW, Lee WM, Lei X, Lellouch J, Leo S, Leone S, Lewis JD, Li D, Li H, Li L, Li QZ, Lim JK, Limosani A, Lincoln D, Linnemann J, Lipaev VV, Lipeles E, Lipton R, Lister A, Liu H, Liu Q, Liu T, Liu Y, Lobodenko A, Lockwitz S, Loginov A, Lokajicek M, Lopes de Sa R, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Luna-Garcia R, Lungu G, Lyon AL, Lys J, Lysak R, Maciel AKA, Madar R, Madrak R, Maestro P, Magaña-Villalba R, Malik S, Malik S, Malyshev VL, Manca G, Manousakis-Katsikakis A, Mansour J, Marchese L, Margaroli F, Marino P, Martínez-Ortega J, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McCarthy R, McGivern CL, McNulty R, Mehta A, Mehtala P, Meijer MM, Melnitchouk A, Menezes D, Mercadante PG, Merkin M, Mesropian C, Meyer A, Meyer J, Miao T, Miconi F, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Mondal NK, Moon CS, Moore R, Morello MJ, Mukherjee A, Mulhearn M, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nagy E, Nakano I, Napier A, Narain M, Nayyar R, Neal HA, Negret JP, Nett J, Neustroev P, Nguyen HT, Nigmanov T, Nodulman L, Noh SY, Norniella O, Nunnemann T, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Orduna J, Ortolan L, Osman N, Pagliarone C, Pal A, Palencia E, Palni P, Papadimitriou V, Parashar N, Parihar V, Park SK, Parker W, Partridge R, Parua N, Patwa A, Pauletta G, Paulini M, Paus C, Penning B, Perfilov M, Peters Y, Petridis K, Petrillo G, Pétroff P, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pleier MA, Podstavkov VM, Pondrom L, Popov AV, Poprocki S, Potamianos K, Pranko A, Prewitt M, Price D, Prokopenko N, Prokoshin F, Ptohos F, Punzi G, Qian J, Quadt A, Quinn B, Ratoff PN, Razumov I, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ripp-Baudot I, Ristori L, Rizatdinova F, Robson A, Rodriguez T, Rolli S, Rominsky M, Ronzani M, Roser R, Rosner JL, Ross A, Royon C, Rubinov P, Ruchti R, Ruffini F, Ruiz A, Russ J, Rusu V, Sajot G, Sakumoto WK, Sakurai Y, Sánchez-Hernández A, Sanders MP, Santi L, Santos AS, Sato K, Savage G, Saveliev V, Savitskyi M, Savoy-Navarro A, Sawyer L, Scanlon T, Schamberger RD, Scheglov Y, Schellman H, Schlabach P, Schmidt EE, Schott M, Schwanenberger C, Schwarz T, Schwienhorst R, Scodellaro L, Scuri F, Seidel S, Seiya Y, Sekaric J, Semenov A, Severini H, Sforza F, Shabalina E, Shalhout SZ, Shary V, Shaw S, Shchukin AA, Shears T, Shepard PF, Shimojima M, Shkola O, Shochet M, Shreyber-Tecker I, Simak V, Simonenko A, Skubic P, Slattery P, Sliwa K, Smith JR, Snider FD, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song H, Sonnenschein L, Sorin V, Soustruznik K, St Denis R, Stancari M, Stark J, Stefaniuk N, Stentz D, Stoyanova DA, Strauss M, Strologas J, Sudo Y, Sukhanov A, Suslov I, Suter L, Svoisky P, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Titov M, Toback D, Tokar S, Tokmenin VV, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Totaro P, Trovato M, Tsai YT, Tsybychev D, Tuchming B, Tully C, Ukegawa F, Uozumi S, Uvarov L, Uvarov S, Uzunyan S, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vázquez F, Velev G, Vellidis C, Verkheev AY, Vernieri C, Vertogradov LS, Verzocchi M, Vesterinen M, Vidal M, Vilanova D, Vilar R, Vizán J, Vogel M, Vokac P, Volpi G, Wagner P, Wahl HD, Wallny R, Wang MHLS, Wang SM, Warchol J, Waters D, Watts G, Wayne M, Weichert J, Welty-Rieger L, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Williams MRJ, Wilson GW, Wilson JS, Wilson P, Winer BL, Wittich P, Wobisch M, Wolbers S, Wolfmeister H, Wood DR, Wright T, Wu X, Wu Z, Wyatt TR, Xie Y, Yamada R, Yamamoto K, Yamato D, Yang S, Yang T, Yang UK, Yang YC, Yao WM, Yasuda T, Yatsunenko YA, Ye W, Ye Z, Yeh GP, Yi K, Yin H, Yip K, Yoh J, Yorita K, Yoshida T, Youn SW, Yu GB, Yu I, Yu JM, Zanetti AM, Zeng Y, Zennamo J, Zhao TG, Zhou B, Zhou C, Zhu J, Zielinski M, Zieminska D, Zivkovic L, Zucchelli S. Combined Forward-Backward Asymmetry Measurements in Top-Antitop Quark Production at the Tevatron. PHYSICAL REVIEW LETTERS 2018; 120:042001. [PMID: 29437406 DOI: 10.1103/physrevlett.120.042001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Indexed: 06/08/2023]
Abstract
The CDF and D0 experiments at the Fermilab Tevatron have measured the asymmetry between yields of forward- and backward-produced top and antitop quarks based on their rapidity difference and the asymmetry between their decay leptons. These measurements use the full data sets collected in proton-antiproton collisions at a center-of-mass energy of sqrt[s]=1.96 TeV. We report the results of combinations of the inclusive asymmetries and their differential dependencies on relevant kinematic quantities. The combined inclusive asymmetry is A_{FB}^{tt[over ¯]}=0.128±0.025. The combined inclusive and differential asymmetries are consistent with recent standard model predictions.
Collapse
|
37
|
Blum K, Gold M, Modestino EJ, Baron D, Boyett B, Siwicki D, Lott L, Podesta A, Roy AK, Hauser M, Downs BW, Badgaiyan RD. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? ACTA ACUST UNITED AC 2018; 4. [PMID: 31750006 PMCID: PMC6865059 DOI: 10.15761/jsin.1000196] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Prescriptions for Benzodiazepines (BZDs) have risen continually. According to national statistics, the combination of BZDs with opioids has increased since 1999. BZDs (sometimes called “benzos”) work to calm or sedate a person by raising the level of the inhibitory neurotransmitter GABA in the brain. In terms of neurochemistry, BZDs act at the GABAA receptors to inhibit excitatory neurons, reducing VTA glutaminergic drive to reduce dopamine release at the Nucleus accumbens. Benzodiazepine Use Disorder (BUD) is very difficult to treat, partly because BZDs are used to reduce anxiety which paradoxically induces hypodopaminergia. Considering this, we are proposing a paradigm shift. Instead of simply targeting chloride channel direct GABAA receptors for replacement or substitution therapy, we propose the induction of dopamine homeostasis. Our rationale is supported by the well-established notion that the root cause of drug and non-drug addictions (i.e. Reward Deficiency Syndrome [RDS]), at least in adults, involve dopaminergic dysfunction and heightened stress. This proposition involves coupling the Genetic Addiction Risk Score (GARS) with a subsequent polymorphic matched genetic customized Pro-Dopamine Regulator known as KB220ZPBM (Precision Behavioral Management). Induction of dopamine homeostasis will be clinically beneficial in attempts to combat BUD for at least three reasons: 1) During detoxification of alcoholism, the potential induction of dopamine regulation reduces the need for BZDs; 2) A major reason for BZD abuse is because people want to achieve stress reduction and subsequently, the potential induction of dopamine regulation acts as an anti-stress factor; and 3) BUD and OUD are known to reduce resting state functional connectivity, and as such, potential induction of dopamine regulation enhances resting state functional connectivity. Future randomized placebo-controlled studies will investigate this forward thinking proposed novel modality.
Collapse
|
38
|
Quinn P, Pearson C, Cheung A, King J, Chan D, Marchand B, Rudaks D, Quach A, Ferrante A, Gold M. P84: COMBINED IMMUNODEFICIENCY DUE TO DEFICIENCY OF ACTINRELATED PROTEIN COMPLEX 1B (ARPC1B). Intern Med J 2017. [DOI: 10.1111/imj.84_13578] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Chan D, King J, Dzeladini L, Marchand B, Gold M, Quinn P. P78: RUXOLITINIB USE IN A CHILD WITH CHRONIC MUCOCUTANEOUS CANDIDIASIS AND AUTOSOMAL DOMINANT SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GAIN OF FUNCTION (STAT1 GOF) MUTATION. Intern Med J 2017. [DOI: 10.1111/imj.78_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Marchand B, Rudaks D, Gold M, Chan D, Quinn P. P79: INFECTED DERMATITIS ASSOCIATED WITH HTLV-1: A COPYCAT FOR CHILDHOOD CUTANEOUS CONDITIONS. Intern Med J 2017. [DOI: 10.1111/imj.79_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Gold M, Omari T, Abu-Assi R, Moore D, Heine R, Tobin JM, McCall L, Savage K, Ferris L, Kritas S, Davidson G. P34: DIAGNOSTIC MARKERS IN RELATION TO CHALLENGE-PROVEN INFANT COW’S MILK PROTEIN ALLERGY. Intern Med J 2017. [DOI: 10.1111/imj.34_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Gold M, Chan D, Marchand B, Dzeladini L, King J, Cheung A, Quinn P. P80: INTUSSCEPTION: A NOVEL PRESENTATION OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE-Δ (PI3KΔ) SYNDROME (APDS). Intern Med J 2017. [DOI: 10.1111/imj.80_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Marchand B, Gold M, Quinn P, Chan D. P91: NOVEL TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS. Intern Med J 2017. [DOI: 10.1111/imj.91_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
44
|
Finlayson F, Wilson J, Gold M. 356 Potential utility of the Supportive and Palliative Care Indicators Tool (SPICT™) in end-of-life care for non-transplanted adults (NTxA) with cystic fibrosis (CF). J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30693-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
45
|
Gold M, Dayer P, Faye MCAS, Clair G, Seck A, Niang S, Morgenroth E, Strande L. Locally produced natural conditioners for dewatering of faecal sludge. ENVIRONMENTAL TECHNOLOGY 2016; 37:2802-2814. [PMID: 26984372 PMCID: PMC5020332 DOI: 10.1080/09593330.2016.1165293] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 03/07/2016] [Indexed: 05/29/2023]
Abstract
In urban areas of low-income countries, treatment of faecal sludge (FS) is insufficient or non-existent. This results in large amounts of FS being dumped into the environment. Existing treatment technologies for FS, such as settling-thickening tanks and drying beds, are land intensive which is limiting in urban areas. Enhanced settling and dewatering by conditioning was evaluated in order to reduce the treatment footprint (or increase treatment capacity). Conventional wastewater conditioners, such as commercially available lime and polymers, are expensive, and commonly rely on complex supply chains for use in low-income countries. Therefore, the treatment performance of five conditioners which could be produced locally was evaluated: Moringa oleifera seeds and press cake, Jatropha curcas seeds, Jatropha Calotropis leaves and chitosan. M. oleifera seeds and press cake, and chitosan improved settling and dewatering and had a similar performance compared to lime and polymers. Optimal dosages were 400-500 kg M. oleifera/t TS, 300-800 kg lime/t TS and 25-50 kg polymer solution/t TS. In comparison, chitosan required 1.5-3.75 kg/t TS. These dosages are comparable to those recommended for wastewater (sludge). The results indicate that conditioning of FS can reduce total suspended solids (TSS) in the effluent of settling-thickening tanks by 22-81% and reduce dewatering time with drying beds by 59-97%. This means that the area of drying beds could be reduced by 59-97% with end-use as soil conditioner, or 9-26% as solid fuel. Least expensive options and availability will depend on the local context. In Dakar, Senegal, chitosan produced from shrimp waste appears to be most promising.
Collapse
|
46
|
Bennett AH, Seewald M, Hassinger JA, Harris LH, Martin LA, Gold M. “You can’t give this job away”: being a leader in abortion care. Contraception 2016. [DOI: 10.1016/j.contraception.2016.07.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Rosenstein H, Bennett A, Gold M. Addressing reproductive coercion in family medicine residency programs. Contraception 2016. [DOI: 10.1016/j.contraception.2016.07.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Gold M, Bristow S, Shraga R, Berliss M, Luk J. What influences anti-Mullerian hormone levels? associations with genotype combinations. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Bristow S, Gold M, Shraga R, Berliss M, Hoffman D. FSHR Ser680Asn: correlation with FSH levels. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel J, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes V, Barnett B, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland K, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd H, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Canelli F, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cavalli-Sforza M, Cerri A, Cerrito L, Chen Y, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery M, Conway J, Corbo M, Cordelli M, Cox C, Cox D, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d’Ascenzo N, Datta M, De Barbaro P, Demortier L, Deninno M, Devoto F, d’Errico M, Di Canto A, Di Ruzza B, Dittmann J, D’Onofrio M, Donati S, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Eusebi R, Farrington S, Fernández Ramos J, Field R, Flanagan G, Forrest R, Franklin M, Freeman J, Frisch H, Funakoshi Y, Garfinkel A, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg C, Giokaris N, Giromini P, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw A, Goulianos K, Gramellini E, Grinstein S, Grosso-Pilcher C, Group R, Guimaraes da Costa J, Hahn S, Han J, Happacher F, Hara K, Hare M, Harr R, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes R, Husemann U, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon E, Jindariani S, Jones M, Joo K, Jun S, Junk T, Kambeitz M, Kamon T, Karchin P, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim D, Kim H, Kim J, Kim M, Kim S, Kim S, Kim Y, Kim Y, Kimura N, Kirby M, Knoepfel K, Kondo K, Kong D, Konigsberg J, Kotwal A, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen A, Lammel S, Lancaster M, Lannon K, Latino G, Lee H, Lee J, Leone S, Lewis J, Limosani A, Lipeles E, Liu H, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Margaroli F, Marino P, Martínez M, Matera K, Mattson M, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Mesropian C, Miao T, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon C, Moore R, Morello M, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Neu C, Nigmanov T, Nodulman L, Noh S, Norniella O, Oakes L, Oh S, Oh Y, Oksuzian I, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips T, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Prokoshin F, Pranko A, Ptohos F, Punzi G, Ranjan N, Redondo Fernández I, Renton P, Rescigno M, Riddick T, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner J, Ruffini F, Ruiz A, Russ J, Rusu V, Safonov A, Sakumoto W, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt E, Schwarz T, Scodellaro L, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout S, Shears T, Shepard P, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sinervo P, Sliwa K, Smith J, Snider F, Sorin V, Song H, Stancari M, St. Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng P, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis C, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang S, Warburton A, Waters D, Wester W, Whiteson D, Wicklund A, Wilbur S, Williams H, Wilson J, Wilson P, Winer B, Wittich P, Wolbers S, Wolfe H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang U, Yang Y, Yao WM, Yeh G, Yi K, Yoh J, Yorita K, Yoshida T, Yu G, Yu I, Zanetti A, Zeng Y, Zhou C, Zucchelli S. Measurement of the WWand WZproduction cross section using final states with a charged lepton and heavy-flavor jets in the full CDF Run II data set. Int J Clin Exp Med 2016. [DOI: 10.1103/physrevd.94.032008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|